Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A Reckless Guide to P-values : Local Evidence, Global Errors.

Lew MJ.

Handb Exp Pharmacol. 2020;257:223-256. doi: 10.1007/164_2019_286.

PMID:
31897610
2.

Multi-Component Mechanism of H2 Relaxin Binding to RXFP1 through NanoBRET Kinetic Analysis.

Hoare BL, Bruell S, Sethi A, Gooley PR, Lew MJ, Hossain MA, Inoue A, Scott DJ, Bathgate RAD.

iScience. 2019 Jan 25;11:93-113. doi: 10.1016/j.isci.2018.12.004. Epub 2018 Dec 10.

3.

Cortisol limits selected actions of synthetic glucocorticoids in the airway epithelium.

Prodanovic D, Keenan CR, Langenbach S, Li M, Chen Q, Lew MJ, Stewart AG.

FASEB J. 2018 Mar;32(3):1692-1704. doi: 10.1096/fj.201700730R. Epub 2018 Jan 3.

PMID:
29167235
4.

Biased signalling from the glucocorticoid receptor: Renewed opportunity for tailoring glucocorticoid activity.

Keenan CR, Lew MJ, Stewart AG.

Biochem Pharmacol. 2016 Jul 15;112:6-12. doi: 10.1016/j.bcp.2016.02.008. Epub 2016 Feb 18. Review.

PMID:
26898958
5.

Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling.

Poole DP, Amadesi S, Veldhuis NA, Abogadie FC, Lieu T, Darby W, Liedtke W, Lew MJ, McIntyre P, Bunnett NW.

J Biol Chem. 2013 Feb 22;288(8):5790-802. doi: 10.1074/jbc.M112.438184. Epub 2013 Jan 3.

6.

Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling.

Kuo T, Lew MJ, Mayba O, Harris CA, Speed TP, Wang JC.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11160-5. doi: 10.1073/pnas.1111334109. Epub 2012 Jun 25.

7.

N-glycosylation determines ionic permeability and desensitization of the TRPV1 capsaicin receptor.

Veldhuis NA, Lew MJ, Abogadie FC, Poole DP, Jennings EA, Ivanusic JJ, Eilers H, Bunnett NW, McIntyre P.

J Biol Chem. 2012 Jun 22;287(26):21765-72. doi: 10.1074/jbc.M112.342022. Epub 2012 May 8.

8.

Bad statistical practice in pharmacology (and other basic biomedical disciplines): you probably don't know P.

Lew MJ.

Br J Pharmacol. 2012 Jul;166(5):1559-67. doi: 10.1111/j.1476-5381.2012.01931.x.

9.

Ligand-supported purification of the urotensin-II receptor.

Du AT, Onan D, Dinh DT, Lew MJ, Ziogas J, Aguilar MI, Pattenden LK, Thomas WG.

Mol Pharmacol. 2010 Oct;78(4):639-47. doi: 10.1124/mol.110.065151. Epub 2010 Jul 20.

PMID:
20647393
10.

Estimating the risk of rare complications: is the 'rule of three' good enough?

Ludbrook J, Lew MJ.

ANZ J Surg. 2009 Jul;79(7-8):565-70. doi: 10.1111/j.1445-2197.2009.04994.x.

PMID:
19694672
11.

On contemporaneous controls, unlikely outcomes, boxes and replacing the 'Student': good statistical practice in pharmacology, problem 3.

Lew MJ.

Br J Pharmacol. 2008 Nov;155(6):797-803. doi: 10.1038/bjp.2008.350. Epub 2008 Sep 22. Review.

12.

A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.

Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, Christopoulos A.

J Biol Chem. 2008 Oct 24;283(43):29312-21. doi: 10.1074/jbc.M803801200. Epub 2008 Aug 22.

13.

Principles: when there should be no difference--how to fail to reject the null hypothesis.

Lew MJ.

Trends Pharmacol Sci. 2006 May;27(5):274-8. Epub 2006 Apr 3. Review.

PMID:
16595154
14.
15.

Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors.

Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, Southwell BR, Lew MJ, Thomas WG.

Mol Pharmacol. 2002 Apr;61(4):768-77.

PMID:
11901215
16.

Substrate analogs incorporating beta-amino acids: potential application for peptidase inhibition.

Lew RA, Boulos E, Stewart KM, Perlmutter P, Harte MF, Bond S, Reeve SB, Norman MU, Lew MJ, Aguilar MI, Smith AI.

FASEB J. 2001 Jul;15(9):1664-6. No abstract available.

PMID:
11427520
17.

Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA.

Br J Pharmacol. 2001 Mar;132(6):1281-91.

18.

Beyond eyeballing: fitting models to experimental data.

Christopoulos A, Lew MJ.

Crit Rev Biochem Mol Biol. 2000;35(5):359-91. Review. No abstract available.

PMID:
11099051
19.

Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists.

Lew MJ, Ziogas J, Christopoulos A.

Trends Pharmacol Sci. 2000 Oct;21(10):376-81. Review.

PMID:
11050317
20.

The assessment of antagonist potency under conditions of transient response kinetics.

Christopoulos A, Parsons AM, Lew MJ, El-Fakahany EE.

Eur J Pharmacol. 1999 Oct 15;382(3):217-27.

PMID:
10556673
21.

Role of disulfide bridges in the folding, structure and biological activity of omega-conotoxin GVIA.

Flinn JP, Pallaghy PK, Lew MJ, Murphy R, Angus JA, Norton RS.

Biochim Biophys Acta. 1999 Sep 14;1434(1):177-90.

PMID:
10556572
22.

Examination of adenosine receptor-mediated relaxation of the pig coronary artery.

Lew MJ, Kao SW.

Clin Exp Pharmacol Physiol. 1999 May-Jun;26(5-6):438-43.

PMID:
10386235
23.

Roles of key functional groups in omega-conotoxin GVIA synthesis, structure and functional assay of selected peptide analogues.

Flinn JP, Pallaghy PK, Lew MJ, Murphy R, Angus JA, Norton RS.

Eur J Biochem. 1999 Jun;262(2):447-55.

24.
25.

An improved method for analysis of competitive agonist/antagonist interactions by non-linear regression.

Lew MJ, Angus JA.

Ann N Y Acad Sci. 1997 May 30;812:179-81. No abstract available.

PMID:
9186736
26.

Structure-function relationships of omega-conotoxin GVIA. Synthesis, structure, calcium channel binding, and functional assay of alanine-substituted analogues.

Lew MJ, Flinn JP, Pallaghy PK, Murphy R, Whorlow SL, Wright CE, Norton RS, Angus JA.

J Biol Chem. 1997 May 2;272(18):12014-23.

27.
29.

Synthesis and biological characterization of a series of analogues of omega-conotoxin GVIA.

Flinn JP, Murphy R, Boublik JH, Lew MJ, Wright CE, Angus JA.

J Pept Sci. 1995 Nov-Dec;1(6):379-84.

PMID:
9223017
30.

Analysis of competitive agonist-antagonist interactions by nonlinear regression.

Lew MJ, Angus JA.

Trends Pharmacol Sci. 1995 Oct;16(10):328-37. Review.

PMID:
7491710
32.

The effect of high perfusion rates on the endothelial diffusion barrier in rat mesenteric arteries in vitro.

Lew MJ, Madeley LJ.

Clin Exp Pharmacol Physiol. 1994 Jun;21(6):501-8.

PMID:
7982281
33.

Interpretation of the acetylcholine test of endothelial cell dysfunction in hypertension.

Angus JA, Lew MJ.

J Hypertens Suppl. 1992 Dec;10(7):S179-86. Review.

PMID:
1291652
35.

Access of blood-borne vasoconstrictors to the arteriolar smooth muscle.

Lew MJ, Duling BR.

J Vasc Res. 1992 Jul-Aug;29(4):341-6.

PMID:
1391555
36.

Arteriolar reactivity in vivo is influenced by an intramural diffusion barrier.

Lew MJ, Duling BR.

Am J Physiol. 1990 Aug;259(2 Pt 2):H574-81.

PMID:
1974741
37.

Arteriolar smooth muscle responses are modulated by an intramural diffusion barrier.

Lew MJ, Rivers RJ, Duling BR.

Am J Physiol. 1989 Jul;257(1 Pt 2):H10-6.

PMID:
2568755
38.

Release of endogenous ATP during sympathetic nerve stimulation.

Lew MJ, White TD.

Br J Pharmacol. 1987 Oct;92(2):349-55.

39.

Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially.

Lew MJ, Ludbrook J, Pavia JM, Quail AW, Rutter PC.

J Pharmacol Methods. 1987 Apr;17(2):137-48.

PMID:
2884351
41.
42.

Phentolamine--an unexpected agonist in the rabbit.

Angus JA, Lew MJ.

Br J Pharmacol. 1984 Mar;81(3):423-5.

43.
44.
45.
46.

Characterization of the clonidine receptor site.

Korner PI, Angus JA, Lew MJ, Heinzow BG.

Chest. 1983 Feb;83(2 Suppl):345-9.

PMID:
6295710
47.

Supplemental Content

Support Center